ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

Eli Lilly's shares rose 2% after the FDA lifted the shortage of anti-obesity drugs, including Mounjaro, alongside Novo Nordisk's Ozempic and Wegovy.

The FDA has resolved shortages for Eli Lilly's weight-loss drug Zepbound, confirming that the supply is now adequate to meet current and future demand.

Eli Lilly excels in healthcare, especially with its weight-loss and diabetes drugs, significantly impacting the Fidelity Select Pharmaceuticals fund, which has a 27% stake in the company.